NB S101, a dual acting bone agent, has a demonstrated ability to decrease resorption of bone while maintaining formation of new bone. The drug has been formulated as a convenient once-daily tablet.
Philip Young, Osteologix president and CEO, said: “This is an important step in the process of developing this exciting compound and we look forward to working with the agency as we prepare for the next clinical trials.”